US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
GB9620795D0
(en)
*
|
1996-10-05 |
1996-11-20 |
Smithkline Beecham Plc |
Vaccines
|
AUPO517897A0
(en)
|
1997-02-19 |
1997-04-11 |
Csl Limited |
Chelating immunostimulating complexes
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
AUPO732997A0
(en)
*
|
1997-06-12 |
1997-07-03 |
Csl Limited |
Ganglioside immunostimulating complexes and uses thereof
|
ES2500490T3
(es)
*
|
1997-08-29 |
2014-09-30 |
Antigenics Inc. |
Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
|
GB9718901D0
(en)
|
1997-09-05 |
1997-11-12 |
Smithkline Beecham Biolog |
Vaccine
|
JP4426091B2
(ja)
*
|
1997-09-05 |
2010-03-03 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
サポニンを含有する水中油型エマルション
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
DE69929310T2
(de)
|
1998-02-05 |
2006-08-03 |
Glaxosmithkline Biologicals S.A. |
Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
CN1629185B
(zh)
|
1998-04-07 |
2011-11-02 |
科里克萨公司 |
结核杆菌抗原融合蛋白及其应用
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
GB9817052D0
(en)
*
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
NZ509974A
(en)
|
1998-08-07 |
2003-10-31 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for use thereof
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
AU750587B2
(en)
|
1998-10-16 |
2002-07-25 |
Smithkline Beecham Biologicals (Sa) |
Adjuvant systems and vaccines
|
KR20070108263A
(ko)
|
1998-12-08 |
2007-11-08 |
코릭사 코포레이션 |
클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를포함하는 약제학적 조성물 및 진단 키트
|
AU1580300A
(en)
|
1998-12-08 |
2000-06-26 |
Smithkline Beecham Biologicals (Sa) |
Novel compounds
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
NZ513935A
(en)
|
1999-02-17 |
2004-02-27 |
Csl Ltd |
Immunogenic complexes and methods relating thereto
|
ES2228454T3
(es)
*
|
1999-02-26 |
2005-04-16 |
Chiron S.R.L. |
Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg.
|
DK1163343T3
(da)
|
1999-03-12 |
2010-04-19 |
Glaxosmithkline Biolog Sa |
Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
|
JP4846906B2
(ja)
*
|
1999-03-19 |
2011-12-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
GB9909077D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
EP2028190A1
(en)
|
1999-04-02 |
2009-02-25 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
DE60014076T2
(de)
|
1999-04-19 |
2005-10-13 |
Glaxosmithkline Biologicals S.A. |
Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
US7166573B1
(en)
|
1999-05-28 |
2007-01-23 |
Ludwig Institute For Cancer Research |
Breast, gastric and prostate cancer associated antigens and uses therefor
|
US6432411B1
(en)
*
|
1999-07-13 |
2002-08-13 |
Hawaii Biotechnology Group |
Recombinant envelope vaccine against flavivirus infection
|
GB9918319D0
(en)
|
1999-08-03 |
1999-10-06 |
Smithkline Beecham Biolog |
Vaccine composition
|
GB9923176D0
(en)
|
1999-09-30 |
1999-12-01 |
Smithkline Beecham Biolog |
Novel composition
|
DK1227837T3
(da)
|
1999-10-22 |
2008-09-15 |
Aventis Pasteur |
Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
|
US6905712B2
(en)
|
1999-12-08 |
2005-06-14 |
Statens Veterinarmedicinska Anstalt |
Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
|
AU2243801A
(en)
*
|
1999-12-08 |
2001-06-18 |
Statens Veterinarmedicinska Anstalt |
Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
|
KR100919916B1
(ko)
|
2000-02-23 |
2009-10-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
종양 특이적 동물 단백질
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
CA2396762A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Corixa Corporation |
Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
|
US20030175700A1
(en)
|
2000-04-21 |
2003-09-18 |
Ajay Bhatia |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
WO2001085932A2
(en)
|
2000-05-10 |
2001-11-15 |
Aventis Pasteur Limited |
Immunogenic polypeptides encoded by mage minigenes and uses thereof
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
SK288007B6
(sk)
|
2000-06-29 |
2012-10-02 |
Glaxosmithkline Biologicals S. A. |
Multivalent vaccine composition, process for its producing, and its use
|
GB0108364D0
(en)
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
UA79735C2
(uk)
|
2000-08-10 |
2007-07-25 |
Глаксосмітклайн Байолоджікалз С.А. |
Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
|
US7022830B2
(en)
|
2000-08-17 |
2006-04-04 |
Tripep Ab |
Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
|
RU2286172C2
(ru)
|
2000-08-17 |
2006-10-27 |
Трипеп Аб |
Вакцины, содержащие рибавирин, и способы их использования
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
US20050019340A1
(en)
*
|
2000-10-18 |
2005-01-27 |
Nathalie Garcon |
Vaccines
|
NZ525320A
(en)
*
|
2000-10-18 |
2004-10-29 |
Glaxosmithkline Biolog S |
Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants
|
EP1201250A1
(en)
*
|
2000-10-25 |
2002-05-02 |
SMITHKLINE BEECHAM BIOLOGICALS s.a. |
Immunogenic compositions comprising liver stage malarial antigens
|
WO2002058727A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Walter Reed Army Institute Of Research |
Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
|
US7306806B2
(en)
|
2001-01-26 |
2007-12-11 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant P. falciparum merozoite protein-142 vaccine
|
GB0103171D0
(en)
|
2001-02-08 |
2001-03-28 |
Smithkline Beecham Biolog |
Vaccine composition
|
US20040071734A1
(en)
*
|
2001-02-23 |
2004-04-15 |
Nathalie Garcon |
Novel vaccine
|
US20040096463A1
(en)
*
|
2001-02-23 |
2004-05-20 |
Nathalie Garcon |
Novel vaccine
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
US7713942B2
(en)
*
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
EP1417236A4
(en)
|
2001-07-10 |
2010-03-17 |
Corixa Corp |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ENCAPSULATED PROTEINS AND ADJUVANTS IN MICROSPHERES
|
MXPA04000653A
(es)
|
2001-07-27 |
2004-11-22 |
Chiron Srl |
Adhesinas de meningococcus nada, app y orf 40.
|
GB0118367D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxosmithkline Biolog Sa |
Novel use
|
US20030138434A1
(en)
*
|
2001-08-13 |
2003-07-24 |
Campbell Robert L. |
Agents for enhancing the immune response
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
GB0123580D0
(en)
*
|
2001-10-01 |
2001-11-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
DE10211088A1
(de)
|
2002-03-13 |
2003-09-25 |
Ugur Sahin |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
US6861410B1
(en)
|
2002-03-21 |
2005-03-01 |
Chiron Corporation |
Immunological adjuvant compositions
|
EP2330113B1
(en)
|
2002-04-19 |
2016-06-29 |
The Governing Council Of The University Of Toronto |
Immunological methods and compositions for the treatment of Alzheimer's disease
|
EP1523582B1
(en)
|
2002-07-18 |
2008-11-12 |
University of Washington |
Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
|
PL399492A1
(pl)
|
2002-08-02 |
2012-11-19 |
Glaxosmithkline Biologicals S.A. |
Szczepionka
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
JP5404990B2
(ja)
|
2002-10-23 |
2014-02-05 |
グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム |
マラリアに対するワクチン接種の方法
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
CA2511907A1
(en)
|
2003-01-06 |
2004-07-22 |
Wyeth |
Compositions and methods for diagnosing and treating colon cancers
|
JP2006515024A
(ja)
|
2003-01-29 |
2006-05-18 |
ファイザー・プロダクツ・インク |
Bordetellabronchisepticaに対するイヌワクチン
|
US20050089533A1
(en)
*
|
2003-01-29 |
2005-04-28 |
Joseph Frantz |
Canine vaccines against Bordetella bronchiseptica
|
EP2191844B1
(en)
|
2003-01-30 |
2014-03-05 |
Novartis AG |
Injectable vaccines against multiple meningococcal serogroups
|
CN1767854B
(zh)
|
2003-04-04 |
2013-07-24 |
硕腾P有限责任公司 |
微流化水包油乳剂及疫苗组合物
|
WO2005032457A2
(en)
|
2003-07-21 |
2005-04-14 |
Boyce Thompson Institute For Plant Research, Inc. |
Vectors and methods for immunization against norwalk virus using transgenic plants
|
CA2532369C
(en)
|
2003-07-31 |
2016-07-26 |
Chiron Corporation |
Immunogenic compositions for streptococcus pyogenes
|
DE10341812A1
(de)
|
2003-09-10 |
2005-04-07 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
DE10344799A1
(de)
|
2003-09-26 |
2005-04-14 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
ES2346314T3
(es)
|
2003-10-02 |
2010-10-14 |
Glaxosmithkline Biolog Sa |
Antigenos de b. pertussis y uso de los mismos en vacunacion.
|
CN103405761A
(zh)
|
2003-10-02 |
2013-11-27 |
诺华疫苗和诊断有限公司 |
多种脑膜炎球菌血清群的液体疫苗
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
JP5030594B2
(ja)
|
2003-12-23 |
2012-09-19 |
アルボー ビータ コーポレーション |
Hpvの発癌性株に対する抗体およびそれらの使用方法
|
EP2561884B1
(en)
|
2004-02-05 |
2017-01-04 |
The Ohio State University Research Foundation |
Chimeric VEGF peptides
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
CA2559371C
(en)
|
2004-03-09 |
2014-07-08 |
Chiron Corporation |
Influenza virus vaccines
|
JP5393978B2
(ja)
*
|
2004-04-05 |
2014-01-22 |
ゾエティス・ピー・エルエルシー |
マイクロ流動化された水中油型乳剤及びワクチン組成物
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
EP2272531A3
(en)
|
2004-04-30 |
2011-04-13 |
Novartis Vaccines and Diagnostics S.r.l. |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
DE102004023187A1
(de)
|
2004-05-11 |
2005-12-01 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
DE102004024617A1
(de)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
DE602005025342D1
(de)
|
2004-05-28 |
2011-01-27 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
US20060165716A1
(en)
|
2004-07-29 |
2006-07-27 |
Telford John L |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0420634D0
(en)
*
|
2004-09-16 |
2004-10-20 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP1804833A2
(en)
|
2004-09-22 |
2007-07-11 |
GlaxoSmithKline Biologicals SA |
Staphylococcal immunogenic compositions
|
EP1797173B1
(en)
|
2004-10-08 |
2014-05-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Modulation of replicative fitness by using less frequently used synonymous codons
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CN101072875B
(zh)
|
2004-12-07 |
2011-05-18 |
东丽株式会社 |
新型癌抗原肽及其用途
|
US8916165B2
(en)
|
2004-12-15 |
2014-12-23 |
Janssen Alzheimer Immunotherapy |
Humanized Aβ antibodies for use in improving cognition
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
LT2351772T
(lt)
|
2005-02-18 |
2016-10-10 |
Glaxosmithkline Biologicals Sa |
Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
|
GB0504436D0
(en)
*
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NZ561823A
(en)
|
2005-03-23 |
2010-04-30 |
Glaxosmithkline Biolog Sa |
Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
|
DE102005013846A1
(de)
|
2005-03-24 |
2006-10-05 |
Ganymed Pharmaceuticals Ag |
Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
|
US8541007B2
(en)
|
2005-03-31 |
2013-09-24 |
Glaxosmithkline Biologicals S.A. |
Vaccines against chlamydial infection
|
CA2602637A1
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
DK1877426T3
(da)
|
2005-04-29 |
2012-05-14 |
Glaxosmithkline Biolog Sa |
Fremgangsmåde til forebyggelse eller behandling af M Tuberculosis-infektion.
|
JP5222134B2
(ja)
|
2005-06-15 |
2013-06-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
Her−2ペプチド
|
GB0513421D0
(en)
*
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP1910410B1
(en)
|
2005-07-01 |
2011-10-26 |
Forsyth Dental Infirmary for Children |
Tuberculosis antigen detection assays and vaccines
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
GB0519871D0
(en)
|
2005-09-30 |
2005-11-09 |
Secr Defence |
Immunogenic agents
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
NZ567817A
(en)
|
2005-11-01 |
2012-01-12 |
Novartis Vaccines & Diagnostic |
Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
DK2368572T3
(da)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
|
AU2006335256B2
(en)
|
2005-11-22 |
2012-10-18 |
Novartis Vaccines And Diagnostics, Inc. |
Norovirus and sapovirus antigens
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
DE102005059242A1
(de)
|
2005-12-12 |
2007-06-14 |
Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten |
Molekulare Marker für eine Tumordiagnose und -therapie
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101378778B
(zh)
|
2005-12-22 |
2013-02-06 |
葛兰素史密丝克莱恩生物有限公司 |
肺炎球菌多糖缀合物疫苗
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
JP5275814B2
(ja)
|
2006-01-17 |
2013-08-28 |
フオルスレン,アルネ |
新規表面露出ヘモフィルス・インフルエンザ(HAEMOPHILUSINFLUENZAE)タンパク質(タンパク質E;pE)
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
WO2007109813A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
WO2007126816A2
(en)
|
2006-03-30 |
2007-11-08 |
Embrex, Inc. |
Methods and compositions for vaccination of poultry
|
EP2476433A1
(en)
|
2006-03-30 |
2012-07-18 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
WO2009017467A1
(en)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Treatment of amyloidogenic diseases
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
EP2390363A1
(en)
|
2006-06-02 |
2011-11-30 |
GlaxoSmithKline Biologicals s.a. |
Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the PRF1 gene
|
PL2054431T3
(pl)
|
2006-06-09 |
2012-07-31 |
Novartis Ag |
Konformery adhezyn bakteryjnych
|
JP5275982B2
(ja)
|
2006-06-12 |
2013-08-28 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
ワクチン
|
NZ573931A
(en)
|
2006-06-29 |
2012-03-30 |
Craig J Venter Inst Inc |
Polypeptides from neisseria meningitidis
|
PT2043682E
(pt)
|
2006-07-17 |
2014-07-11 |
Glaxosmithkline Biolog Sa |
Vacina da influenza
|
NZ574239A
(en)
|
2006-07-18 |
2011-12-22 |
Glaxosmithkline Biolog Sa |
Hybrid fusion proteins for malaria vaccines
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
WO2008012538A2
(en)
|
2006-07-25 |
2008-01-31 |
The Secretary Of State For Defence |
Live vaccine strains of francisella
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
PT2097102E
(pt)
|
2006-09-07 |
2012-08-03 |
Glaxosmithkline Biolog Sa |
Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
SI2068918T1
(sl)
*
|
2006-09-26 |
2012-09-28 |
Infectious Disease Res Inst |
Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
|
BRPI0717219B8
(pt)
|
2006-10-12 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
composição imunogênica, e, uso de uma composição imunogênica
|
EP2086582B1
(en)
|
2006-10-12 |
2012-11-14 |
GlaxoSmithKline Biologicals s.a. |
Vaccine comprising an oil in water emulsion adjuvant
|
JP5301455B2
(ja)
*
|
2006-11-20 |
2013-09-25 |
デューコム |
癌を治療するためのキラヤサポニンを含む脂質含有粒子の使用
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
SI2137210T1
(sl)
|
2007-03-02 |
2017-01-31 |
Glaxosmithkline Biologicals S.A. |
Nov postopek in sestavki
|
MX351247B
(es)
|
2007-04-04 |
2017-10-05 |
Infectious Disease Res Institute Star |
Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2152903A2
(en)
|
2007-04-26 |
2010-02-17 |
Ludwig Institute for Cancer Research, Ltd. |
Methods for diagnosing and treating astrocytomas
|
US20100074918A1
(en)
|
2007-05-02 |
2010-03-25 |
Jan Poolman |
Vaccine
|
US20110097360A1
(en)
|
2007-05-25 |
2011-04-28 |
Claudio Donati |
Streptococcus pneumoniae pilus antigens
|
GB0711858D0
(en)
*
|
2007-06-19 |
2007-07-25 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AU2008267208B2
(en)
|
2007-06-26 |
2012-01-19 |
Glaxosmithkline Biologicals S.A. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
CA2692200A1
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
PL2173376T3
(pl)
|
2007-08-02 |
2015-08-31 |
Biondvax Pharmaceuticals Ltd |
Multimeryczne wieloepitopowe szczepionki przeciwko grypie
|
US20100260791A1
(en)
|
2007-08-03 |
2010-10-14 |
President And Fellows Of Harvard |
Chlamydia antigens
|
US9066899B2
(en)
|
2007-08-13 |
2015-06-30 |
Glaxosmithkline Biologicals Sa |
Vaccines
|
EP2185195A2
(en)
|
2007-08-16 |
2010-05-19 |
Tripep Ab |
Immunogen platform
|
US8287885B2
(en)
|
2007-09-12 |
2012-10-16 |
Novartis Ag |
GAS57 mutant antigens and GAS57 antibodies
|
EP2201131B8
(en)
|
2007-09-17 |
2014-12-10 |
MDxHealth SA |
Improved methylation detection
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
EP2060583A1
(en)
|
2007-10-23 |
2009-05-20 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
CN104906597B
(zh)
|
2007-10-25 |
2018-07-10 |
东丽株式会社 |
免疫诱导剂
|
EP2062594A1
(en)
|
2007-11-21 |
2009-05-27 |
Wyeth Farma, S.A. |
Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8637053B2
(en)
|
2007-12-03 |
2014-01-28 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
WO2009081274A2
(en)
|
2007-12-21 |
2009-07-02 |
Novartis Ag |
Mutant forms of streptolysin o
|
SI2222710T1
(sl)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Rekombinatni RSV antigeni
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
EP2889042A3
(en)
|
2008-03-18 |
2015-10-14 |
Novartis AG |
Improvements in preparation of influenza virus vaccine antigens
|
RS54306B1
(en)
|
2008-04-16 |
2016-02-29 |
Glaxosmithkline Biologicals S.A. |
THE VACCINE
|
ES2651924T3
(es)
|
2008-04-18 |
2018-01-30 |
The General Hospital Corporation |
Inmunoterapias que emplean vacunas autoensamblantes
|
WO2009131673A1
(en)
|
2008-04-25 |
2009-10-29 |
Ludwig Institute For Cancer Research Ltd. |
Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
JP5689796B2
(ja)
|
2008-08-01 |
2015-03-25 |
ガマ ワクチンズ ピーティワイ リミテッド |
インフルエンザワクチン
|
PT2324842E
(pt)
|
2008-08-05 |
2015-07-21 |
Toray Industries |
Agente de indução de imunidade
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
EP2356225A1
(en)
|
2008-12-03 |
2011-08-17 |
Protea Vaccine Technologies Ltd. |
GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
|
CN103897045A
(zh)
|
2009-01-12 |
2014-07-02 |
诺华股份有限公司 |
抗革兰氏阳性细菌疫苗中的Cna_B结构域
|
GB0900455D0
(en)
|
2009-01-13 |
2009-02-11 |
Secr Defence |
Vaccine
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20100234283A1
(en)
|
2009-02-04 |
2010-09-16 |
The Ohio State University Research Foundation |
Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
|
PL2396032T3
(pl)
|
2009-02-10 |
2017-05-31 |
Seqirus UK Limited |
Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
|
WO2010094663A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxosmithkline Biologicals S.A. |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
EP2221375A1
(en)
|
2009-02-20 |
2010-08-25 |
Ganymed Pharmaceuticals AG |
Methods and compositions for diagnosis and treatment of cancer
|
EP2221063A1
(en)
|
2009-02-20 |
2010-08-25 |
Ganymed Pharmaceuticals AG |
Methods and compositions for diagnosis and treatment of cancer
|
CN107028969A
(zh)
|
2009-02-20 |
2017-08-11 |
加尼梅德药物公司 |
用于癌症诊断和治疗的方法和组合物
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
MX2011009597A
(es)
|
2009-03-17 |
2012-05-29 |
Glaxosmithkline Biolog Sa |
Deteccion mejorada de la expresion del gen.
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
EP2249159A1
(en)
|
2009-04-29 |
2010-11-10 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated markers for diagnosis and therapy
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
GB0910046D0
(en)
*
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
GB0910045D0
(en)
*
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
EP2442826B1
(en)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Influenza vaccine, composition, and methods of use
|
US20100316673A1
(en)
|
2009-06-16 |
2010-12-16 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
WO2010149743A2
(en)
|
2009-06-24 |
2010-12-29 |
Id Biomedical Corporation Of Quebec |
Vaccine
|
CA2766211A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
JP5646620B2
(ja)
|
2009-07-17 |
2014-12-24 |
インダストリー アカデミック コーポレーション ファウンデーション, ハルリム ユニバーシティー |
リポソームに被包されたオリゴヌクレオチド及びエピトープを含む免疫増強用組成物
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CN102596980A
(zh)
|
2009-08-26 |
2012-07-18 |
Rna公司 |
源自脂磷壁酸的糖脂及含有该糖脂的组合物
|
CN104650241A
(zh)
|
2009-08-27 |
2015-05-27 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
WO2011025542A1
(en)
|
2009-08-31 |
2011-03-03 |
Ludwig Institute For Cancer Research Ltd. |
Seromic analysis of ovarian cancer
|
US20110110980A1
(en)
|
2009-09-02 |
2011-05-12 |
Wyeth Llc |
Heterlogous prime-boost immunization regimen
|
PL2475384T3
(pl)
*
|
2009-09-10 |
2017-02-28 |
Merial, Inc. |
Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
ES2538007T3
(es)
|
2009-09-16 |
2015-06-16 |
Vaxart, Inc. |
Estrategia de inmunización para prevenir una infección por H1N1
|
GB0917457D0
(en)
|
2009-10-06 |
2009-11-18 |
Glaxosmithkline Biolog Sa |
Method
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
JP2013506651A
(ja)
|
2009-09-30 |
2013-02-28 |
ノバルティス アーゲー |
Staphylococcus.aureus5型および8型莢膜多糖の結合体
|
CN102724988B
(zh)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
脑膜炎球菌fHBP多肽的表达
|
WO2011040978A2
(en)
|
2009-10-02 |
2011-04-07 |
Ludwig Institute For Cancer Research Ltd. |
Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP2322555A1
(en)
|
2009-11-11 |
2011-05-18 |
Ganymed Pharmaceuticals AG |
Antibodies specific for claudin 6 (CLDN6)
|
ES2649389T3
(es)
|
2009-11-11 |
2018-01-11 |
Ganymed Pharmaceuticals Gmbh |
Anticuerpos específicos para claudina 6 (CLDN6)
|
WO2011067758A2
(en)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Immunogenic fragments and multimers from streptococcus pneumoniae proteins
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CN103002910A
(zh)
|
2010-03-10 |
2013-03-27 |
葛兰素史密丝克莱恩生物有限公司 |
疫苗组合物
|
EP2366709A1
(en)
|
2010-03-16 |
2011-09-21 |
BioNTech AG |
Tumor vaccination involving a humoral immune response against self-proteins
|
WO2011113546A1
(en)
|
2010-03-16 |
2011-09-22 |
Biontech Ag |
Tumor vaccination involving a humoral immune response against self-proteins
|
EP2552480A1
(en)
|
2010-03-26 |
2013-02-06 |
GlaxoSmithKline Biologicals S.A. |
Hiv vaccine
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011127316A1
(en)
|
2010-04-07 |
2011-10-13 |
Novartis Ag |
Method for generating a parvovirus b19 virus-like particle
|
EP2558069A1
(en)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Benzonapthyridine compositions and uses thereof
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
SI3170508T1
(sl)
|
2010-06-04 |
2020-01-31 |
Wyeth Llc |
Formulacije cepiva
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
EP2591097A1
(en)
|
2010-07-06 |
2013-05-15 |
Novartis AG |
Norovirus derived immunogenic compositions and methods
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP2404936A1
(en)
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
GB201015132D0
(en)
|
2010-09-10 |
2010-10-27 |
Univ Bristol |
Vaccine composition
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
ME02810B
(me)
|
2010-09-20 |
2018-01-20 |
Biontech Cell & Gene Therapies Gmbh |
Antigen-specifični t ćelijski receptori i t ćelijski epitopi
|
BR112013004582A2
(pt)
|
2010-09-27 |
2016-09-06 |
Crucell Holland Bv |
método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
|
AU2011315447A1
(en)
|
2010-10-15 |
2013-05-09 |
Glaxosmithkline Biologicals S.A. |
Cytomegalovirus gB antigen
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
GB201101331D0
(en)
|
2011-01-26 |
2011-03-09 |
Glaxosmithkline Biolog Sa |
Compositions and uses
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
US20120114688A1
(en)
|
2010-11-08 |
2012-05-10 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
US9352030B2
(en)
|
2010-12-14 |
2016-05-31 |
Glaxosmithkline Biologicals, S.A. |
Mycobacterium antigenic composition
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
PL2667892T3
(pl)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
Schemat szczepień przeciwko rsv
|
EP2667891B1
(en)
|
2011-01-27 |
2021-10-06 |
Gamma Vaccines Pty Limited |
Combination vaccines
|
WO2012114323A1
(en)
|
2011-02-22 |
2012-08-30 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
|
WO2012135177A2
(en)
|
2011-03-29 |
2012-10-04 |
Uab Research Foundation |
Methods and compositions for cytomegalovirus il-10 protein
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
MX350795B
(es)
|
2011-04-08 |
2017-09-19 |
Inmune Design Corp |
Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
RS54627B1
(en)
|
2011-05-13 |
2016-08-31 |
Ganymed Pharmaceuticals Ag |
CANCER EXPRESSION ANTIBODIES THAT EXPLAIN CLAUDINE 6
|
LT2707385T
(lt)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Iš anksto sulieti rsv f antigenai
|
WO2012156391A1
(en)
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
CN103547284B
(zh)
|
2011-05-19 |
2015-11-25 |
东丽株式会社 |
免疫诱导剂
|
KR101988895B1
(ko)
|
2011-05-19 |
2019-06-13 |
도레이 카부시키가이샤 |
면역 유도제
|
BR112013029834A8
(pt)
|
2011-05-24 |
2022-10-18 |
Biontech Ag |
vacinas individualizadas para câncer
|
RS59369B1
(sr)
|
2011-05-24 |
2019-11-29 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizovane vakcine protiv kancera
|
WO2012159643A1
(en)
|
2011-05-24 |
2012-11-29 |
Biontech Ag |
Individualized vaccines for cancer
|
CA2838188C
(en)
|
2011-06-04 |
2017-04-18 |
Rochester General Hospital Research Institute |
Compositions and methods related to p6 of haemophilus influenzae
|
CA2837651A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
EP3508219A1
(en)
|
2011-07-06 |
2019-07-10 |
GlaxoSmithKline Biologicals S.A. |
Self-replicating rna prime - protein boost vaccines
|
EP2729178A1
(en)
|
2011-07-08 |
2014-05-14 |
Novartis AG |
Tyrosine ligation process
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201114919D0
(en)
|
2011-08-30 |
2011-10-12 |
Glaxosmithkline Biolog Sa |
Method
|
WO2013038375A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Methods for making saccharide-protein glycoconjugates
|
PT2758432T
(pt)
|
2011-09-16 |
2019-06-14 |
Ucb Biopharma Sprl |
Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
EP2780034A1
(en)
|
2011-11-14 |
2014-09-24 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
PL2782598T3
(pl)
|
2011-11-23 |
2021-03-08 |
In3Bio Ltd. |
Rekombinowane białka i ich zastosowania terapeutyczne
|
EP3750544A3
(en)
|
2011-11-30 |
2021-03-24 |
Emory University |
Jak inhibitors for use in the prevention or treatment of viral infection
|
WO2013079687A1
(en)
|
2011-11-30 |
2013-06-06 |
The Chancellor, Masters And Scholars Of The University Of Oxford |
Inkt cell modulators and methods of using the same
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
ES2729967T3
(es)
|
2012-02-07 |
2019-11-07 |
Infectious Disease Res Inst |
Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
|
WO2013134577A2
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen, Inc. |
Leishmaniasis antigen detection assays and vaccines
|
WO2013150518A1
(en)
|
2012-04-01 |
2013-10-10 |
Rappaport Family Institute For Research In The Medical Sciences |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
PT2850431T
(pt)
|
2012-05-16 |
2018-07-23 |
Immune Design Corp |
Vacinas para hsv-2
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
EP2869842A1
(en)
|
2012-07-06 |
2015-05-13 |
Novartis AG |
Immunogenic compositions and uses thereof
|
GB201213364D0
(en)
|
2012-07-27 |
2012-09-12 |
Glaxosmithkline Biolog Sa |
Purification process
|
ES2969734T3
(es)
|
2012-08-03 |
2024-05-22 |
Access To Advanced Health Inst |
Composiciones y métodos para tratar una infección activa por Mycobacterium tuberculosis
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
AU2013320313B2
(en)
|
2012-09-18 |
2018-07-12 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
JP2015532276A
(ja)
|
2012-10-02 |
2015-11-09 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
非直鎖状糖コンジュゲート
|
CA2896552A1
(en)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Immunogenic compositions
|
BR112015009229B1
(pt)
|
2012-10-24 |
2021-07-20 |
Platelet Targeted Therapeutics, Llc |
Composição tendo como alvo a expressão de genes para plaquetas, uso de uma célula tronco compreendendo a referida composição para tratar hemofilia e método in vitro ou ex vivo para gerar uma célula tronco modificada
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
US10155031B2
(en)
|
2012-11-28 |
2018-12-18 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
LT2928489T
(lt)
|
2012-12-05 |
2019-04-10 |
Glaxosmithkline Biologicals S.A. |
Imunogeninė kompozicija
|
UY34506A
(es)
|
2012-12-10 |
2014-06-30 |
Fernando Amaury Ferreira Chiesa |
Adyuvante de vacunación, preparación y vacunas que lo contienen
|
EP3608332B1
(en)
|
2013-03-15 |
2022-06-01 |
GlaxoSmithKline Biologicals SA |
Vaccine against human rhinovirus
|
CA2904506A1
(en)
|
2013-03-15 |
2014-09-18 |
Bioven 3 Limited |
Self-assembling synthetic proteins
|
BR112015024860B1
(pt)
|
2013-03-28 |
2023-11-07 |
Access To Advanced Health Institute |
Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
|
JP6426706B2
(ja)
|
2013-04-18 |
2018-11-21 |
イミューン デザイン コーポレイション |
がん処置で使用するためのgla単剤療法
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
KR20160027019A
(ko)
|
2013-06-26 |
2016-03-09 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
뎅기 바이러스 백신에 대한 방법 및 조성물
|
EP3777882A1
(en)
|
2013-07-30 |
2021-02-17 |
BioNTech SE |
Tumor antigens for determining cancer therapy
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
BE1022008B1
(fr)
|
2013-08-05 |
2016-02-03 |
Glaxosmithkline Biologicals S.A. |
Compositions immunogenes combinees
|
JP6306700B2
(ja)
|
2013-11-01 |
2018-04-04 |
ユニバーシティ オブ オスロUniversity of Oslo |
アルブミン改変体及びその使用
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
CA2929126C
(en)
|
2013-11-13 |
2020-01-07 |
University Of Oslo |
Outer membrane vesicles and uses thereof
|
EP3069138B1
(en)
|
2013-11-15 |
2019-01-09 |
Oslo Universitetssykehus HF |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015077442A2
(en)
|
2013-11-20 |
2015-05-28 |
La Jolla Institute For Allergy And Immunology |
Grass pollen immunogens and methods and uses for immune response modulation
|
AU2014352986A1
(en)
|
2013-11-20 |
2016-06-16 |
Alk-Abello A/S |
Pan pollen immunogens and methods and uses thereof for immune response modulation
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
JP6741580B2
(ja)
|
2013-12-31 |
2020-08-19 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
単一バイアルのワクチン製剤
|
IL247301B
(en)
|
2014-02-20 |
2022-07-01 |
Vaxart Inc |
Formulations for administration to the small intestine
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
WO2015131053A1
(en)
|
2014-02-28 |
2015-09-03 |
Alk-Abelló A/S |
Polypeptides derived from phl p and methods and uses thereof for immune response modulation
|
JP6608422B2
(ja)
*
|
2014-03-25 |
2019-11-20 |
ザ ガバメント オブ ザ ユナイテッド ステイツ,アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー |
モノホスホリルリピッドa(mpla)含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤
|
BE1022744B1
(fr)
|
2014-03-26 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
Antigenes staphylococciques mutants
|
GB201405921D0
(en)
*
|
2014-04-02 |
2014-05-14 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
CA2951430A1
(en)
|
2014-06-13 |
2015-12-17 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
ES2749701T3
(es)
|
2014-06-25 |
2020-03-23 |
Glaxosmithkline Biologicals Sa |
Composición inmunógena de Clostridium difficile
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
AR101256A1
(es)
|
2014-07-21 |
2016-12-07 |
Sanofi Pasteur |
Composición vacunal que comprende ipv y ciclodextrinas
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
WO2016062323A1
(en)
|
2014-10-20 |
2016-04-28 |
Biontech Ag |
Methods and compositions for diagnosis and treatment of cancer
|
MY179251A
(en)
|
2014-11-02 |
2020-11-02 |
Univ North Carolina Chapel Hill |
Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
|
MX2017007652A
(es)
|
2014-12-10 |
2017-10-11 |
Glaxosmithkline Biologicals Sa |
Metodo de tratamiento.
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
MX2017010698A
(es)
|
2015-02-20 |
2018-04-30 |
Univ Texas |
Metodos y composiciones para chlamydia atenuada como vacuna y vector.
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
EP4226937A3
(en)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
WO2016154010A1
(en)
|
2015-03-20 |
2016-09-29 |
Makidon Paul |
Immunogenic compositions for use in vaccination against bordetella
|
ES2970824T3
(es)
|
2015-03-26 |
2024-05-30 |
Gpn Vaccines Pty Ltd |
Vacuna estreptocócica
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
KR20240031420A
(ko)
|
2015-06-12 |
2024-03-07 |
박사르트, 인크. |
Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
|
EP3138579A1
(en)
|
2015-09-05 |
2017-03-08 |
Biomay Ag |
Fusion protein for use in the treatment of a hepatitis b virus infection
|
SG11201803209QA
(en)
*
|
2015-10-19 |
2018-05-30 |
Cadila Healthcare Ltd |
New adjuvant and vaccine composition containing the same
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
GB201522132D0
(en)
*
|
2015-12-15 |
2016-01-27 |
Glaxosmithkline Biolog Sa |
Vaccine
|
BE1024160B9
(fr)
|
2015-12-22 |
2017-12-06 |
Glaxosmithkline Biologicals Sa |
Formulation immunogène
|
GB201603625D0
(en)
|
2016-03-02 |
2016-04-13 |
Glaxosmithkline Biolog Sa |
Novel influenza antigens
|
CN109562154A
(zh)
|
2016-03-10 |
2019-04-02 |
爱普瑞希斯有限公司 |
带有修饰hsp70域的抗原结合融合蛋白
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
CA3011887A1
(en)
|
2016-03-14 |
2017-09-21 |
Stian FOSS |
Engineered immunoglobulins with altered fcrn binding
|
CA3017711A1
(en)
|
2016-03-28 |
2017-10-05 |
Toray Industries, Inc. |
Immunity-inducing agent
|
WO2017167768A1
(en)
|
2016-03-28 |
2017-10-05 |
Glaxosmithkline Biologicals S.A. |
Novel vaccine composition
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
JP2019521095A
(ja)
|
2016-05-21 |
2019-07-25 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
AU2017299162A1
(en)
|
2016-07-20 |
2019-02-07 |
BioNTech SE |
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
|
EP3504230A1
(en)
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
WO2018053294A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
EP3295956A1
(en)
|
2016-09-20 |
2018-03-21 |
Biomay Ag |
Polypeptide construct comprising fragments of allergens
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
WO2018077385A1
(en)
|
2016-10-25 |
2018-05-03 |
Biontech Rna Pharmaceuticals Gmbh |
Dose determination for immunotherapeutic agents
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
EP3600391A1
(en)
|
2017-03-31 |
2020-02-05 |
GlaxoSmithKline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
SG11201909584QA
(en)
*
|
2017-04-25 |
2019-11-28 |
Adjuvance Technologies Inc |
Triterpene saponin analogues
|
US20210187098A1
(en)
|
2017-04-28 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Vaccination
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
GB2600652B
(en)
*
|
2017-05-30 |
2022-11-02 |
Glaxosmithkline Biologicals Sa |
Novel compositions
|
CN107375921B
(zh)
*
|
2017-06-12 |
2019-10-29 |
商丘美兰生物工程有限公司 |
一种甘草皂苷脂质体免疫佐剂及其制备方法
|
EP3638301A1
(en)
|
2017-06-16 |
2020-04-22 |
GlaxoSmithKline Biologicals S.A. |
Method of treatment
|
WO2019016597A2
(en)
|
2017-07-18 |
2019-01-24 |
Bioven 3 Limited |
SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
|
WO2019034575A1
(en)
|
2017-08-14 |
2019-02-21 |
Glaxosmithkline Biologicals Sa |
METHODS OF AMPLIFYING IMMUNE RESPONSES
|
US11123415B2
(en)
|
2017-08-16 |
2021-09-21 |
Ohio State Innovation Foundation |
Nanoparticle compositions for Salmonella vaccines
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
WO2019048928A1
(en)
|
2017-09-07 |
2019-03-14 |
University Of Oslo |
VACCINE MOLECULES
|
JP7339942B2
(ja)
|
2017-09-08 |
2023-09-06 |
アクセス ツー アドバンスト ヘルス インスティチュート |
サポニンを含むリポソーム製剤および使用方法
|
WO2019079594A1
(en)
|
2017-10-18 |
2019-04-25 |
The University Of North Carolina At Chapel Hill |
METHODS AND COMPOSITIONS FOR VACCINES AGAINST NOVOVIRUS AND DIAGNOSIS OF NOVOVIRUS
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
EP3747459A4
(en)
|
2018-02-02 |
2021-12-01 |
SL Vaxigen, Inc. |
NEW VACCINE IMMUNO ADJUVANS
|
AU2019235424B2
(en)
|
2018-03-15 |
2023-12-21 |
BioNTech SE |
5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing RNA, expressing proteins and in therapy
|
EP3569612A1
(en)
|
2018-05-18 |
2019-11-20 |
Biomay Ag |
Treatment and prevention of house dust mite allergies
|
BR112020024285A2
(pt)
|
2018-06-12 |
2021-03-02 |
Glaxosmithkline Biologicals S.A. |
polinucleotídeos e polipeptídeos de adenovírus
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
CN112601545A
(zh)
|
2018-08-07 |
2021-04-02 |
葛兰素史密丝克莱恩生物有限公司 |
工艺和疫苗
|
US20210220462A1
(en)
|
2018-08-23 |
2021-07-22 |
Glaxosmithkline Biologicals Sa |
Immunogenic proteins and compositions
|
EP3851120A4
(en)
|
2018-09-11 |
2022-04-27 |
Shanghai Public Health Clinical Center |
IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE, AND APPLICATION THEREOF
|
WO2020055503A1
(en)
|
2018-09-14 |
2020-03-19 |
Massachusetts Institute Of Technology |
Nanoparticle vaccine adjuvant and methods of use thereof
|
US20220000779A1
(en)
|
2018-12-06 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
US11419932B2
(en)
|
2019-01-24 |
2022-08-23 |
Massachusetts Institute Of Technology |
Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
|
GB201901608D0
(en)
|
2019-02-06 |
2019-03-27 |
Vib Vzw |
Vaccine adjuvant conjugates
|
WO2020178359A1
(en)
|
2019-03-05 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Hepatitis b immunisation regimen and compositions
|
CA3141577A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
MX2021015922A
(es)
|
2019-06-25 |
2022-03-22 |
In3Bio Ltd |
Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
|
EP3999108A1
(en)
|
2019-07-21 |
2022-05-25 |
GlaxoSmithKline Biologicals S.A. |
Therapeutic viral vaccine
|
WO2021014385A1
(en)
|
2019-07-24 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
BR112021026565A2
(pt)
|
2019-08-05 |
2022-05-03 |
Glaxosmithkline Biologicals Sa |
Composição imunogênica
|
EP3777884A1
(en)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic composition
|
EP3799884A1
(en)
|
2019-10-01 |
2021-04-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
WO2021067785A1
(en)
|
2019-10-02 |
2021-04-08 |
Janssen Vaccines & Prevention B.V |
Staphylococcus peptides and methods of use
|
US20220396797A1
(en)
|
2019-11-15 |
2022-12-15 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
US20230045642A1
(en)
|
2019-12-19 |
2023-02-09 |
Glaxosmithkline Biologicals Sa |
S. aureus antigens and compositions thereof
|
CA3168108A1
(en)
|
2020-01-16 |
2021-07-22 |
Janssen Pharmaceuticals, Inc. |
Fimh mutant, compositions therewith and use thereof
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
US20230293659A1
(en)
|
2020-08-03 |
2023-09-21 |
Glaxosmithkline Biologicals Sa |
Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
|
US11225508B1
(en)
|
2020-09-23 |
2022-01-18 |
The University Of North Carolina At Chapel Hill |
Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
|
US20230416309A1
(en)
|
2020-10-23 |
2023-12-28 |
Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji |
Fusion protein and application thereof
|
JP2023547197A
(ja)
|
2020-10-28 |
2023-11-09 |
サノフィ・パスツール |
Tlr4アゴニストを含有するリポソーム、その製造および使用
|
IL303334A
(en)
|
2020-12-02 |
2023-07-01 |
Glaxosmithkline Biologicals Sa |
The perfect fimh by a donor strand
|
MX2023008251A
(es)
|
2021-01-12 |
2023-07-26 |
Janssen Pharmaceuticals Inc |
Mutantes de fimh, composiciones con estos y uso de estos.
|
EP4032547A1
(en)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce derived fragements for the treatment of hsv
|
JP2024510717A
(ja)
|
2021-02-22 |
2024-03-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物、使用及び方法
|
EP4304640A1
(en)
|
2021-03-12 |
2024-01-17 |
Northwestern University |
Antiviral vaccines using spherical nucleic acids
|
EP4313138A1
(en)
|
2021-03-30 |
2024-02-07 |
Viravaxx AG |
Sars-cov-2 subunit vaccine
|
WO2022207793A1
(en)
|
2021-03-31 |
2022-10-06 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
MX2023011697A
(es)
|
2021-04-01 |
2023-10-19 |
Janssen Pharmaceuticals Inc |
Produccion de bioconjugados o18 de e. coli.
|
EP4362974A1
(en)
|
2021-06-28 |
2024-05-08 |
GlaxoSmithKline Biologicals S.A. |
Novel influenza antigens
|
CN118019754A
(zh)
|
2021-09-23 |
2024-05-10 |
维拉瓦克斯股份公司 |
诱导pres特异性中和抗体的hbv疫苗
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
US20230190920A1
(en)
|
2021-12-19 |
2023-06-22 |
Massachusetts Institute Of Technology |
Compositions and methods for long-lasting germinal center responses to a priming immunization
|
WO2023144665A1
(en)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Modified human cytomegalovirus proteins
|
WO2023154960A1
(en)
|
2022-02-14 |
2023-08-17 |
University Of Georgia Research Foundation, Inc. |
Pan-pneumovirus vaccine compositions and methods of use thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|